Grounded in science, we explore and validate novel targets with rigor and resolve, paving the way toward breakthrough therapies for immunological diseases and cancer.
We are taking a novel approach to targeting SIRP
Our portfolio of Signal Regulatory Protein (SIRP)–directed antibodies works via a unique mechanism of action and has the potential to address the underlying pathology across a broad range of diseases.
